Mylan Pharmaceuticals Inc.may be regretting its tactic of trying to deflect criticism over big EpiPen price increases by arguing that more than half of the drug’s $608 list price is being absorbed by the drug supply chain, which is leading to calls for more transparency, particularly around pharmacy benefit managers.
The argument raised many more questions than Mylan CEO Heather Bresch was prepared to answer at a House Oversight and Government Reform Committee hearing Sept. 21. And it led to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?